$CURX News

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY

Curanex Continues To Advance Phyto-N As Lead Development Candidate, With Ulcerative Colitis As Initial Target Indication; Co. Prepares Phyto-N For Planned IND Submission In Q4 Of 2026

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives

EXCLUSIVE: Curanex Highlights Five Additional Patient Cases Taking Phyto-N Treatment Supporting Potential Of Its Lead Candidate In Advanced Cancer Supportive Care

EXCLUSIVE: Curanex Highlights Five Additional Patient Cases Taking Phyto-N Treatment Supporting Potential Of Its Lead Candidate In Advanced Cancer Supportive Care

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

EXCLUSIVE: Curanex Highlights Patient Case Study Suggesting Potential Relevance Of Phyto-N For Cancer Supportive Care

EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases

EXCLUSIVE: Curanex Expands Drug Development Pipeline To Include Cancer Cachexia; Co's Phyto-N Currently Advancing Through Preclinical Studies To Prepare For Investigational New Drug Submission

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Curanex Pharmaceuticals Completes Dose-Range Finding Toxicology Study Of Phyto-N; No Findings Of Toxicological Significance At Maximum Feasible Dose

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Curanex Forms World Class Scientific Advisory Board

What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours

Curanex Provides Operational Update on Key Regulatory Milestones